Perennial Allergic Rhinitis Drug Market Size, Share, Analysis, Industry Report and Forecast 2021-2027
The global perennial allergic rhinitis drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Perennial allergic rhinitis is a chronic allergic condition. It causes nasal congestion and a runny nose. Additionally, it doesn’t lessen during certain seasons or months of the year. The major factor accelerating the growth of the market is the rising prevalence of perennial allergic rhinitis.
Moreover, the market is also
growing due to new product launches. For instance, in January 2021, JB
Chemicals and Pharmaceuticals announced that it has received the approval for
abbreviated new drug application (ANDA) for Loratadine tablets USP 10 mg from
the US FDA in the US market. The drug is used to treat allergic rhinitis caused
by pollen and upper respiratory tract allergy. Additionally, in June 2021,
Bayer Healthcare LLC announced that it has received the approval of Astepro
(azelastine hydrochloride nasal spray, 0.15%) from the US FDA. It is used for
the treatment of seasonal and perennial allergic rhinitis for adults and
children six years of age and older.
To Request
a Sample of our Report on Perennial Allergic Rhinitis Drug Market: https://www.omrglobal.com/request-sample/perennial-allergic-rhinitis-drug-market
Some key players in the market
include Merck & Co., Inc., Boehringer Ingelheim GmbH, and Sanofi S.A.,
among others. The market players are contributing significantly to the growth
of the market by the adoption of various strategies including mergers &
acquisitions, geographical expansion, partnerships and collaborations, and new
product launches, to stay competitive in the market. For instance, in January
2022, Glenmark Pharmaceuticals Ltd. announced that its fully owned Swiss
subsidiary Glenmark Specialty S.A. received approval for Ryaltris, a nasal
spray fixed dose prescription drug from the US Food and Drug Administration's
(FDA). It is used for the treatment of seasonal allergic rhinitis.
Market Coverage
·
The market number available for – 2020-2027
·
Base year- 2020
·
Forecast period- 2021-2027
Segment Covered-
·
By Type
·
By Application
Regions Covered-
·
North America
·
Europe
·
Asia-Pacific
·
Rest of the World
Competitive Landscape- Merck & Co., Inc.,
Boehringer Ingelheim GmbH, and Sanofi S.A., among others.
(Get 15% Discount on Buying this Report)
A
full Report of Perennial Allergic Rhinitis Drug Market is Available @ https://www.omrglobal.com/industry-reports/perennial-allergic-rhinitis-drug-market
Global Perennial Allergic Rhinitis Drug Market Report by
Segment
By Type
• APC-3000
• Asapiprant
• Bilastine
• Desloratadine
• Others
By Application
• Clinic
• Hospital
• Others
Global Perennial Allergic Rhinitis Drug Market Report by
Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
·
Latin America
·
Middle East & Africa
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment